期刊
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
卷 54, 期 -, 页码 S53-S62出版社
WILEY
DOI: 10.1111/apt.16607
关键词
-
This article reviews clinical trial efficacy data and survey data on several treatments for IBS-C, emphasizing the importance of standardizing quality of life and symptom metrics in future trials and tailoring treatment selection based on symptom improvement probability, safety, tolerability, and cost.
Background Multiple efficacious therapies are currently available for treating irritable bowel syndrome with constipation (IBS-C). IBS-C specific survey tools that assess symptom relief, treatment satisfaction, and quality of life are important for gauging real-world effectiveness. Aims/Methods This article reviews clinical trial efficacy data as well as survey data on adequate relief and quality of life from pivotal trials for lubiprostone, linaclotide, plecanatide, tenapanor, and tegaserod. A brief discussion of agents in development with novel mechanisms of action is also provided. Results/Conclusions Quality of life and symptom metrics should be standardized and continue to be represented in future IBS-C trials. The choice of agent should be tailored to probability of improving symptoms, safety, tolerability, and cost.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据